- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05926869
Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris
June 23, 2023 updated by: Dr. Parisa Sanawar, Jinnah Postgraduate Medical Centre
Acne vulgaris (AV) is a disease of the pilosebaceous unit that causes noninflammatory lesions (open and closed comedones), inflammatory lesions (papules, pustules, and nodules), and varying degrees of scarring.
The key pathogenic processes includes alteration of follicular keratinization that leads to comedones; increased and altered sebum production under androgen control; follicular colonization by Propionibacterium acnes; .
The role of topical antibiotics in treating acne is well established.
Clindamycin is a topical antibiotic which has been widely used in treatment of acne for many decades.
The extensive use of antibiotics in acne has lead to the development of resistance to antimicrobial therapy.
Dapsone is known to have antibacterial as well as anti-inflammatory action which may help in reduction of acne.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Topical Dapsone 5% gel contains sulfone and has an advanced solvent micro particulate delivery system that enables penetration of stratum corneum .
It is a new topical drug used in the treatment of Moderate Acne Vulgaris.
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Sindh
-
Karachi, Sindh, Pakistan
- JPMC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- moderate acne vulgaris
- either gender
- 20 to 50 yrs
Exclusion Criteria:
- systemic treatment taken
- pregnant or lactating women
- hematological abnormalities
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A Clindamycin gel
|
Clindamycin is a topical antibiotic which has been widely used in treatment of acne for many decades.
Topical Dapsone 5% gel contains sulfone and has an advanced solvent micro particulate delivery system that enables penetration of stratum corneum .
It is a new topical drug used in the treatment of Moderate Acne Vulgaris.
It has antibacterial as well as anti inflammatory effects
|
Experimental: Group B Dapsone gel
|
Clindamycin is a topical antibiotic which has been widely used in treatment of acne for many decades.
Topical Dapsone 5% gel contains sulfone and has an advanced solvent micro particulate delivery system that enables penetration of stratum corneum .
It is a new topical drug used in the treatment of Moderate Acne Vulgaris.
It has antibacterial as well as anti inflammatory effects
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris
Time Frame: It will be assessed upto 03 months
|
Efficacy will be assessed using Global Acne Grading Sore ( GAGS ).
For GAGS (Score 1-18 = mild, score 19-30 = moderate, score 31-38 = severe).
Mean difference of GAGs score before and after the treatment will be calculated.
|
It will be assessed upto 03 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Nazia Jabeen, FCPS, JPMC
- Principal Investigator: KHADIJA ASADULLAH, FCPS, JPMC
- Principal Investigator: FAIZA INAM, FCPS, JPMC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2022
Primary Completion (Actual)
December 1, 2022
Study Completion (Actual)
February 1, 2023
Study Registration Dates
First Submitted
March 22, 2023
First Submitted That Met QC Criteria
June 23, 2023
First Posted (Actual)
July 3, 2023
Study Record Updates
Last Update Posted (Actual)
July 3, 2023
Last Update Submitted That Met QC Criteria
June 23, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Acneiform Eruptions
- Sebaceous Gland Diseases
- Acne Vulgaris
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Leprostatic Agents
- Protein Synthesis Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Folic Acid Antagonists
- Clindamycin
- Clindamycin palmitate
- Clindamycin phosphate
- Dapsone
Other Study ID Numbers
- NO.F.2-81/2022-GENL/250/JPMC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Vulgaris
-
Nexgen Dermatologics, Inc.Unknown
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico
-
Sebacia, Inc.CompletedInflammatory Acne VulgarisUnited States
-
Rejuva Medical AestheticsHealMD, LLCNot yet recruitingAcne Vulgaris (Disorder)United States
-
InMode MD Ltd.Active, not recruitingInflammatory Acne VulgarisUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingModerate to Severe Acne VulgarisChina
-
PollogenLumenis Be Ltd.RecruitingModerate to Severe Acne VulgarisUnited States
-
Boston PharmaceuticalsCompletedModerate to Severe Acne VulgarisUnited States, Canada
-
Bispebjerg HospitalCompleted
-
Actavis Mid-Atlantic LLCCompletedMILD TO SEVERE ACNE VULGARISIndia
Clinical Trials on Clindamycin and Dapsone gel for 03 months
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompletedAcne VulgarisUnited States
-
Torrent Pharmaceuticals LimitedCatawba ResearchCompletedAcne VulgarisUnited States, Belize
-
Stiefel, a GSK CompanyGlaxoSmithKline; Quintiles, Inc.; Rho, Inc.CompletedAcne VulgarisUnited States, Canada, Belize
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompletedAcne Vulgaris | AcneUnited States, Canada, Belize
-
AllerganCompletedAcne VulgarisUnited States
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompleted
-
Padagis LLCCompleted
-
Watson Laboratories, Inc.Completed
-
Zydus Lifesciences LimitedCompletedAcne VulgarisUnited States, India
-
University of Southern CaliforniaCompleted